JP7046092B2 - Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物 - Google Patents
Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物 Download PDFInfo
- Publication number
- JP7046092B2 JP7046092B2 JP2019551913A JP2019551913A JP7046092B2 JP 7046092 B2 JP7046092 B2 JP 7046092B2 JP 2019551913 A JP2019551913 A JP 2019551913A JP 2019551913 A JP2019551913 A JP 2019551913A JP 7046092 B2 JP7046092 B2 JP 7046092B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- substituted
- aryl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662433470P | 2016-12-13 | 2016-12-13 | |
| US62/433,470 | 2016-12-13 | ||
| PCT/US2017/065665 WO2018111787A1 (en) | 2016-12-13 | 2017-12-12 | Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502268A JP2020502268A (ja) | 2020-01-23 |
| JP2020502268A5 JP2020502268A5 (enExample) | 2021-01-07 |
| JP7046092B2 true JP7046092B2 (ja) | 2022-04-01 |
Family
ID=60888685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551913A Active JP7046092B2 (ja) | 2016-12-13 | 2017-12-12 | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤としてのホスフィンオキシドアルキルアミド置換ヘテロアリール化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10294256B2 (enExample) |
| EP (1) | EP3555111B1 (enExample) |
| JP (1) | JP7046092B2 (enExample) |
| KR (1) | KR102602558B1 (enExample) |
| CN (1) | CN110267964B (enExample) |
| AR (1) | AR110351A1 (enExample) |
| ES (1) | ES2907008T3 (enExample) |
| MA (1) | MA48602A (enExample) |
| TW (1) | TW201827423A (enExample) |
| WO (1) | WO2018111787A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY202167A (en) | 2017-11-21 | 2024-04-12 | Bristol Myers Squibb Co | Sulfone pyridine alkyl amide-substituted heteroaryl compounds |
| TW201940483A (zh) | 2018-03-12 | 2019-10-16 | 美商艾伯維有限公司 | 酪胺酸激酶２介導的傳訊之抑制劑 |
| JP7485609B2 (ja) * | 2018-03-22 | 2024-05-16 | ブリストル－マイヤーズ スクイブ カンパニー | ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物 |
| WO2020150473A2 (en) | 2019-01-18 | 2020-07-23 | Dogma Therapeutics, Inc. | Pcsk9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
| CN114787154A (zh) * | 2020-01-19 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Deucravacitinib的晶型及其制备方法和用途 |
| CN122520625A (zh) | 2020-12-22 | 2026-08-07 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物及其制备方法和用途 |
| CN114805438A (zh) * | 2021-01-18 | 2022-07-29 | 正大天晴药业集团股份有限公司 | 含磷酰基的tyk2抑制剂化合物 |
| EP4308556A4 (en) | 2021-03-16 | 2025-02-19 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| CN115724830A (zh) * | 2021-08-31 | 2023-03-03 | 浙江文达医药科技有限公司 | 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法 |
| KR20240111312A (ko) | 2021-10-25 | 2024-07-16 | 카이메라 쎄라퓨틱스 인코포레이티드 | Tyk2 분해제 및 이의 용도 |
| CN117263913A (zh) | 2022-06-20 | 2023-12-22 | 益方生物科技(上海)股份有限公司 | 杂芳基化合物、固体形式、制备方法及其用途 |
| CN117362343A (zh) * | 2022-07-08 | 2024-01-09 | 爱科诺生物医药(香港)有限公司 | 具有选择性抑制tyk2/jak1活性的化合物，包含其的药物组合物，及其应用 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013958A1 (en) | 2003-08-07 | 2005-02-17 | Novartis Ag | Histone deacetylase inhibitors as immunosuppressants |
| WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| WO2010141406A2 (en) | 2009-06-01 | 2010-12-09 | Osi Pharmaceuticals, Inc. | Amino pyrimidine anticancer compounds |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2014074660A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
| WO2014074661A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
| WO2015177266A1 (en) | 2014-05-22 | 2015-11-26 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with egfr inhibitors/antagonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104125947A (zh) * | 2011-12-21 | 2014-10-29 | 生物区欧洲有限公司 | 杂环脲化合物 |
| WO2014181287A1 (en) * | 2013-05-09 | 2014-11-13 | Piramal Enterprises Limited | Heterocyclyl compounds and uses thereof |
| AR094537A1 (es) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa |
-
2017
- 2017-12-12 MA MA048602A patent/MA48602A/fr unknown
- 2017-12-12 AR ARP170103473A patent/AR110351A1/es unknown
- 2017-12-12 US US15/838,434 patent/US10294256B2/en active Active
- 2017-12-12 EP EP17822919.1A patent/EP3555111B1/en active Active
- 2017-12-12 ES ES17822919T patent/ES2907008T3/es active Active
- 2017-12-12 KR KR1020197019993A patent/KR102602558B1/ko active Active
- 2017-12-12 WO PCT/US2017/065665 patent/WO2018111787A1/en not_active Ceased
- 2017-12-12 JP JP2019551913A patent/JP7046092B2/ja active Active
- 2017-12-12 CN CN201780086194.3A patent/CN110267964B/zh active Active
- 2017-12-12 TW TW106143529A patent/TW201827423A/zh unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013958A1 (en) | 2003-08-07 | 2005-02-17 | Novartis Ag | Histone deacetylase inhibitors as immunosuppressants |
| WO2009143389A1 (en) | 2008-05-21 | 2009-11-26 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| WO2010141406A2 (en) | 2009-06-01 | 2010-12-09 | Osi Pharmaceuticals, Inc. | Amino pyrimidine anticancer compounds |
| WO2013169401A1 (en) | 2012-05-05 | 2013-11-14 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2014074660A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES |
| WO2014074661A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHα RESPONSES |
| WO2015177266A1 (en) | 2014-05-22 | 2015-11-26 | Medizinische Universität Wien | Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with egfr inhibitors/antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102602558B1 (ko) | 2023-11-14 |
| US20180162889A1 (en) | 2018-06-14 |
| CN110267964A (zh) | 2019-09-20 |
| ES2907008T3 (es) | 2022-04-21 |
| EP3555111A1 (en) | 2019-10-23 |
| AR110351A1 (es) | 2019-03-20 |
| TW201827423A (zh) | 2018-08-01 |
| EP3555111B1 (en) | 2022-01-26 |
| KR20190091536A (ko) | 2019-08-06 |
| MA48602A (fr) | 2020-03-18 |
| WO2018111787A1 (en) | 2018-06-21 |
| US10294256B2 (en) | 2019-05-21 |
| JP2020502268A (ja) | 2020-01-23 |
| CN110267964B (zh) | 2022-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7490107B2 (ja) | スルホンピリジンアルキルアミド置換ヘテロアリール化合物 | |
| JP6843135B2 (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 | |
| KR102602558B1 (ko) | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서의 포스핀 옥시드 알킬 아미드 치환된 헤테로아릴 화합물 | |
| JP7097875B2 (ja) | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物 | |
| JP7012082B2 (ja) | Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤 | |
| JP7818623B2 (ja) | 置換ヘテロ環化合物 | |
| JP7637626B2 (ja) | アミド二置換のピリジンまたはピリダジン化合物 | |
| JP2021518389A (ja) | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物 | |
| EP4337656A1 (en) | Substituted heterocyclic compounds | |
| KR20240008337A (ko) | 치환된 헤테로시클릭 화합물 | |
| KR20150079678A (ko) | IL-12, IL-23 및/또는 IFNα의 조절에 유용한 알킬 아미드-치환된 피리미딘 화합물 | |
| JP2022525006A (ja) | Ｉｌ－１２、ｉｌ－２３、および／またはｉｆｎアルファ応答の調節剤として有用なイミダゾピリダジン化合物 | |
| EA046543B1 (ru) | Амидзамещенные гетероциклические соединения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201119 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210812 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210907 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211110 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220308 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220322 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7046092 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |